Catherine Delaney, PA
Medical · Los Lunas, NMNPI 1689735466
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,496 and has fallen 97.3% since, to $40 in 2025.
Across 137 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$529
- AbbVie$464
- Boehringer Ingelheim$284
- Lilly USA, LLC$247
- GSK$245
- Amarin Pharma, Inc.$160
- plus $807 from 14 others
What the payments were for
- Food & beverage$2,726100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $529 |
| AbbVie | 24 | $464 |
| Boehringer Ingelheim | 15 | $284 |
| Lilly USA, LLC | 10 | $247 |
| GSK | 12 | $245 |
| Amarin Pharma, Inc. | 24 | $160 |
| Johnson & Johnson | 4 | $159 |
| Abiomed | 1 | $113 |
| Corcept Therapeutics | 5 | $97 |
| Mylan Specialty L.p. | 5 | $83 |
| Biohaven Pharmaceuticals, Inc. | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Novo Nordisk | 3 | $49 |
| Amgen | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Exact Sciences | 2 | $33 |
| Novartis | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,738 in reported general payments places this provider in the 85th percentile of 156 medical providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 98 | $103,714 |
| TrulicityDulaglutide | 39 | $61,858 |
| EliquisApixaban | 60 | $57,314 |
| OzempicSemaglutide | 37 | $53,067 |
| CreonLipase/Protease/Amylase | 11 | $50,760 |
| JanuviaSitagliptin Phosphate | 38 | $43,910 |
| MounjaroTirzepatide | 29 | $34,021 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $25,923 |
| Spiriva RespimatTiotropium Bromide | 34 | $24,159 |
| FarxigaDapagliflozin Propanediol | 21 | $22,098 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $16,579 |
| Spiriva HandihalerTiotropium Bromide | 15 | $16,446 |
| GlyxambiEmpagliflozin/Linagliptin | 19 | $11,144 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $10,181 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $8,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Glyxambi, Stiolto Respimat | $284 | $149,198163 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $247 | $99,15680 claims |
| AbbVieCreon, Linzess, Savella | $464 | $64,40034 claims |
| Novo NordiskOzempic | $49 | $53,06737 claims |
| MerckJanuvia | $15 | $43,91038 claims |
| AstraZenecaFarxiga, Symbicort | $529 | $38,67757 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $245 | $30,38535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 medical providers in New Mexico.
Other medical in Los Lunas
- Rodrigo Perez-ResendizLos Lunas$2K
- Brenda PachecoAcoma$12K
- Paul TapiaAlbuquerque$7K
- Niki NinopoulosAlbuquerque$7K
- William BaconSanta Fe$6K
- Katie JoshiAlbuquerque$6K
- Loretta GonzalesAlbuquerque$5K
- Sarah East BrumanaRoswell$5K
- Ruben FrancoAlbuquerque$4K
- Bradford GwytherAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.